VYNE Therapeutics (VYNE)
(Real Time Quote from BATS)
$1.80 USD
+0.03 (1.70%)
Updated Aug 9, 2024 12:38 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VYNE 1.80 +0.03(1.70%)
Will VYNE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VYNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYNE
Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
VYNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Here's Why VYNE Therapeutics Inc. (VYNE) Is a Great 'Buy the Bottom' Stock Now
Other News for VYNE
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics announces granting of composition of matter patent for VYN202
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
12 Health Care Stocks Moving In Thursday's Intraday Session